News & Events

Press Releases

Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform

Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics

Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting

Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform

Events

11th Annual Tumor Models Conference

Jul 12 - Jul 13

Listen to Webcast

EHA 2023 Hybrid Congress

Jun 8 - Jun 11

https://ehaweb.org/congress/eha2023-hybrid-congress/eha2023/ Frankfurt, Germany + Google Map

BIO International Convention

Jun 5 - Jun 7

Listen to Webcast

AACR ANNUAL MEETING 2023

Apr 14 - Apr 19

In the News

Precision Medicine Online

Salarius Pharmaceuticals Cleared to Begin Phase I Trial of SP-3164 in Non-Hodgkin Lymphoma

Global Newswire

Salarius Expands Oncology Pipeline Through Acquisition of Targeted Protein Degradation Portfolio from DeuteRx, LLC

The Clinical Trials Guru

David Arthur, Salarius CEO Speaks with Dan Sfera of The Clinical Trials Guru

Houston Business Journal

Salarius Pharmaceuticals raises millions for expanded clinical trial, moves office in TMC

15 Biotech Companies in Houston Making a Major Impact on Medicine

Empowered Patient Podcast

Targeting Epigenetic Causes of Ewing’s Sarcoma with David Arthur Salarius Pharmaceuticals on Empowered Patient Podcast with Karen Jagoda